Sarah L. Sammons, MD

home / authors / sarah-l-sammons-md

Articles

Joyce O'Shaughnessy, MD;Neil M. Iyengar, MD;Sarah L. Sammons, MD;Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Novel Agents Under Study for HR+/HER2- MBC

Joyce O'Shaughnessy, MD;Sarah L. Sammons, MD;Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

A panel of breast oncologists highlight exciting treatment strategies being explored in clinical trials to help address treatment limitations in HR+/HER2- metastatic breast cancer.

Sequencing Therapy in HR+/HER2- MBC

Joyce O'Shaughnessy, MD;Neil M. Iyengar, MD;Sarah L. Sammons, MD;Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

Managing Patients With HR+ MBC on PI3K Therapy

Joyce O'Shaughnessy, MD;Gabriel Hortobagyi, MD, MACP, FASCO;Sarah L. Sammons, MD;Neil M. Iyengar, MD

November 22nd 2021

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases

Carey K. Anders, MD, Duke Cancer Institute;Sarah L. Sammons, MD

June 5th 2020

Collectively, there are more options than ever in the space of HER2-positive breast cancer brain metastases, a significant advance for our hundreds and thousands of patients facing this challenging disease.